Clinical performance of class II MOD fiber reinforced resin composite restorations: an 18-month randomized controlled clinical trial

II类MOD纤维增强树脂复合材料修复体的临床性能:一项为期18个月的随机对照临床试验

阅读:1

Abstract

BACKGROUND: In recent years, there have been suggestions for new restorative strategies that aim to effectively utilize modern adhesive technologies and protect the remaining intact tooth structure. This study was conducted to evaluate the clinical performance of fiber reinforced resin composites in restoring Class II MOD cavities over 18 months. METHODS: Forty-five participants with class II MOD cavities were randomly enrolled. The participants were allocated to three groups (n = 15): Group (1) short glass fiber reinforced resin composite (EverX Posterior), Group (2) polyethylene fiber (Ribbond-Ultra) reinforced resin composite and Group (3) only conventional resin composite (Filtek Z250). The modified USPHS criteria were used to evaluate the restorations at baseline; and at three, six, 12 and 18 months. The categorical data were reported as frequencies and percentages. Intergroup comparisons were analyzed using Chi-Square test after Bonferroni correction (P ≤ 0.016). Comparisons within each group were analyzed using Cochran's Q test after Bonferroni correction (P ≤ 0.005). RESULTS: Intergroup comparisons revealed no statistically significant differences in any of the evaluated criteria except for color match. Compared with the other groups, the short glass fiber-reinforced restoration group presented significantly fewer color matches at different follow-up periods. CONCLUSIONS: Class II direct fiber-reinforced resin composite restorations can offer acceptable performance similar to the nanohybrid resin composite through 18-month of clinical service. CLINICAL SIGNIFICANCE: Fiber reinforcement of resin composites could be a reliable technique for restoring posterior cavities considering factors such as application complexity, cost and aesthetic considerations. TRIAL REGISTRATION: The trial was registered retrospectively on (19/05/2022) at https://clinicaltrials.gov with the ID (NCT05380973).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。